Global Cancer Technology: GCT-007 for Glioblastoma

What this is

A diligence framework for evaluating glioblastoma therapeutic programs, hung on GCT-007 as the nominal subject.

It contains no GCT-007-specific mechanism, trial phase, or preclinical result. This is a framework for the category, not company-specific analysis, and it is not medical advice.

Why GBM is hard

• Blood-brain barrier constraints.
• Tumor heterogeneity.
• Toxicity that limits effective dosing.
• Endpoint selection that may not capture meaningful benefit even when something is working.
• Unmet need is high and outcomes remain poor for many patients, which is exactly why early signals get over-read. Preclinical signals often do not survive real-world biology.

Evidence checklist

• Mechanism: is the target clinically relevant in GBM specifically?
• BBB reality: what evidence supports meaningful CNS exposure?
• Preclinical quality: which models, replicated by whom, at what dosing relevance?
• Clinical path: endpoints, patient selection, combination strategy.

Risks

• Safety and toxicity limiting the dose that would actually work.
• Trial design and endpoint selection risk.
• Financing risk across multi-year development, with expensive trials and long timelines.
• Competitive landscape and shifts in standard of care.
• The dominant risk is translation: CNS exposure, heterogeneity, and endpoints that do not capture meaningful benefit.

Disclosure

GigHz holds a personal position or exposure in this company. That is disclosed here because you should weigh it.

Informational only. Not an offer to sell securities or a solicitation to buy, and not financial, medical, legal or tax advice. Past performance does not guarantee future results.

Informational only. Not investment, medical, legal, or tax advice. GigHz or its founder may hold a position in the company discussed — see the disclosure above.

Written and reviewed by Pouyan Golshani, MD — April 2026